Galera Therapeutics Raises $11 Million in Series A Financing

Galera Therapeutics Raises $11 Million in Series A Financing

Galera Therapeutics, Inc., a biotechnology company focused on the development of breakthrough drugs targeting oxygen metabolic pathways in cancer, fibrosis and other human diseases, today announced an $11 million Series A venture capital financing. The round is co-led by New Enterprise Associates (NEA) and Novartis Venture Fund (NVF) and includes Correlation Ventures. Proceeds will be used to expand clinical development of Galera’s small molecule therapeutics.

Galera also named Mel Sorensen, M.D., President and Chief Executive Officer. Dr. Sorensen brings extensive industry experience to Galera, most recently serving as President and CEO of Ascenta Therapeutics and previously holding senior positions at GlaxoSmithKline and Bayer. Robert Beardsley, Ph.D., a founder and acting CEO of Galera prior to Dr. Sorensen’s appointment, will now serve as Executive Chair of the Board of Directors.

“Galera’s dismutase mimetics, as true small-molecule mimics of the critical enzymes in the oxygen metabolic pathways, overcome the limitations of prior approaches to controlling superoxide and its harmful roles in human disease,” said Dr. Beardsley. “This funding and the leadership team we've assembled allow Galera to pursue the exciting and novel therapeutic potential of these pathways. We are delighted to have Mel lead the company as it moves into validating our candidates in critical unmet medical needs.”

Joining Dr. Beardsley on Galera’s Board of Directors are Frank Torti, M.D., and Jim Barrett, Ph.D., of NEA; Campbell Murray, M.D., and Henry Skinner, Ph.D., of Novartis BioVentures, and Dr. Sorensen. The company also announced that it will relocate its headquarters from St. Louis to the Greater Philadelphia area.

“Clinical and pre-clinical studies suggest that the superoxide pathway is a particularly promising target for drug development,” said Dr. Sorensen. “With initial clinical safety tests completed for Galera’s lead candidates, we look forward to confirming its utility, initially in patients with mucositis due to chemoradiation therapy for head and neck cancer, and subsequently in fibrosis and as an anticancer therapeutic.”

“Dismutase enzymes represent an exceptional opportunity for powerful new drugs,” said Dr. Barrett, a General Partner at NEA. "Galera’s small molecule drugs offer the potential to unlock this potent biology.”

"We are enthusiastic about Galera’s drug candidates because of their potentially broad applicability in several serious diseases,” added Dr. Murray, Managing Director at the Novartis Venture Fund. “It is especially exciting to be able to begin clinical validation immediately. We look forward to working with Mel and the Galera team to realize the substantial therapeutic value of their development portfolio.”

Galera Therapeutics, LLC, was founded by an experienced team of drug developers with seed support from BioGenerator, the St. Louis Arch Angels, ABC Laboratories, and the Center for Emerging Technologies. Its dismutase mimetics have demonstrated initial safety in human studies and potent pre-clinical activity, both in attacking tumors and in protecting normal tissue from diseases such as fibrosis and damage such as radiation.

Suggested Articles

UCB’s bispecific antibody recently beat Johnson & Johnson’s Stelara at clearing psoriasis symptoms, and now it has bested AbbVie’s Humira, too.

FDA staff took the action in response to cases of early growth plate closure in children on the retinoic acid receptor gamma agonist.

The CTAD presentation cleared up some questions about the data set without delivering a telling blow for either side of the debate.